Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
9:525–527 © 1995 Lippincott-Raven Publishers, Philadelphia

Journal of Acquired Immune Deficiency Syndrome
Volume 9, 1995

Author Index

Ades AE, 490
Aiuti F, 450
Alam J, 145
Allan JS, 429
Ancelle-Park RA, 74, 297
Anderson RM, 500
Andersson S, 422
Andrews E, 280
Andrulis DP, 193

Balliet K, 97
Bariou C, 243
Batungwanayo J, 415
Bellin E, 315
Bennett CL, 286
Bennett JM, 138
Bernstein B, 97
Besemer D, 264
Biberfeld G, 1, 422
Biberfeld P, 1
Blakley SA, 43
Blattner W, 81
Blázquez MV, 389
Bogaerts J, 415
Boineau F, 415
Bonis J, 318
Böttiger D, 1
Braithwaite A, 81
Brandon W, 43, 133
Brasky K, 429
Bremermann HJ, 459
Broussard S, 429
Brown N, 280
Brunet J-B, 74
Buffington CA, 11
Busch MP, 305
Butler T, 429

Cagnon L, 349
Cameron DW, 274
Canque B, 204
Carrigan D, 97
Carrigan DR, 69
Cartier F, 243
Caspary WF, 20
Cassileth BR, 286
Ceccherini-Nelli L, 311
Cegielski JP, 408
Chang GY, 332
Chan-Yan C, 162
Cheng-Mayer C, 429
Chernesky MA, 523
Chesney MA, 30
Chin DP, 176
Clark R, 133
Clark RA, 43
Clark SJ, 305
Clotet B, 98
Coates TJ, 30
Cocroft J, 371
Cohn S, 89, 291
Colimon R, 243
Collier AC, 145
Conley LJ, 291
Cook D, 172
Coombs R, 145
Corey L, 145
Cote T, 313
Coutlée F, 257
Craib KJP, 162
Cucchiarini M, 349
Curry R, 99

Daar E, 305
Dabis F, 415
de Thé G, 316
DeHovitz JA, 286
Delmas M-C, 74
Denis F, 318
Dias F, 422
Dimitrov D, 126
D'Offizi G, 450
Doglio A, 349
Downs AM, 74, 297
Driver JA, 168

Eastman PS, 264
Eggert E, 145
Ekman M, 1
Eldridge RR, 208

Fan J, 321
Fanning T, 371
Farzadegan H, 305
Fauci AS, 442
Feichtinger H, 1
Feldstein ML, 138
Feng C-q, 103
Fenoglio D, 227
Fernández-Arcás N, 389
Ferraris A, 227
Figueroa JP, 81
Fine N, 249
Fischer H, 20
Fiscus SA, 51
Flomenberg P, 97
Folds JD, 51
Fox I, 145
Franceschi S, 313
Francke S, 114
Frenz M, 20
Frick R, 114

Galai N, 89
Galli R, 523
Garcia-Moll M, 429
Garnett GP, 500
Geddes M, 313
Genetet N, 243
Gessain A, 316
Ginsberg CA, 193
Giovannetti A, 450
Gluckman JC, 204
Goldenberg RL, 401
Gomez M, 98
Gonzalez PC, 176
Gonzalez-Scarano F, 332
Gregory B, 523
Griffin DE, 379
Griffin JW, 379
Grimison B, 58
Gu Z, 123
Guillonneau M, 209
Guist'hau O, 243
Gutierrez E, 97
Gutta PV, 249
Gwinn M, 514

Hadley WK, 176
Halpern J, 100
Harris PJ, 99
Hartke JR, 11
Hauck W, 371
Hawley-Foss N, 274

Hayes KA, 11, 114
Hayes R, 81
Heggem-Snow A, 51
Heinze-Lacey B, 168
Heisterkamp SH, 74
Helm EB, 20
Heneine W, 99
Henrard DR, 305
Hitimana D-G, 415
Hogg RS, 162
Höjeberg B, 484
Hollinger FB, 126
Holmberg SD, 291
Hopewell PC, 176
Horsburgh CRJr, 176
Hubbard G, 429
Hubert J, 340
Hughes PF, 208

Jacquelinet C, 243
Jacquez JA, 101, 315
Jacqz-Aigrain E, 209
Jang D, 523
Jarvis JN, 249
Jenkins RA, 36
Jiang Y, 103
Johansson I, 422
Johnson MT, 321
Jurado R, 389

Kaaya EE, 1
Kahn JG, 183
Kahn JO, 138
Kamal M, 274
Kan VL, 206
Kaplan JE, 89, 99
Karon J, 514
Katzenstein DA, 100, 183
Kessous-Elbaz A, 257
Khabbaz R, 99
Khabbaz RF, 89
Khadir A, 257
Khurranna AK, 208, 238
King A, 172
Kishimoto T, 321
Kissinger P, 133
Klaskala W, 395
Know KK, 69
Kolberg J, 264
Koopman JS, 101, 315
Korn AP, 361
Korosi-Ronco J, 162
Kozal MJ, 100
Krown SE, 138
Kumar RM, 208, 238
Kunkl A, 227

LaFon S, 280
Lahart C, 126
Lallinger GJ, 408
Landay A, 99
Landers DV, 361
Laughlin MA, 332
Laurence J, 58
Lefebvre J-C, 349
Lembcke B, 20
Lepage P, 415
Lepri AC, 313
Leroy V, 415
Levy JA, 429
Li J, 429
Li Pira G, 227
Li Q-g, 103
Li RC, 274
Li S-L, 1
Li Y-z, 103
Liang Y, 103
Lin S, 138
Link H, 484
Liu M, 321
Ljungdahl Å, 484
Lobaina L, 123
Long PM, 249
Longini IMJr, 315
Longini IRJr, 101
Luby SP, 291
Luciw P, 429
Luppi M, 311
Lurie P, 30

Machado F, 123
MacRae D, 314
Madueño JA, 389
Mahony JB, 523
Manca F, 227
Mandelbrot L, 209
Manyenga D, 408
Marion SA, 172
Markson L, 371
Martin Z, 123
Mathes LE, 11, 114
Mato J, 123
Matuieux R, 316
Maza-Martinez O, 321
McArthur JC, 379
McFarland W, 183
McGregor CM, 193
McNeil JI, 206
Merigan TC, 100
Metroka CE, 138
Mezzaroma I, 450
Michelet C, 243
Middleton PJ, 172
Miller WC, 408
Miranda L, 123
Miyazaki M, 312
Mlalasi J, 408
Mocroft AA, 100
Mollicone B, 450
Montaner JSG, 162, 172
Morgan WM, 395
Moroni M, 311
Morse A, 133
Mouneimne Y, 126
Msellati P, 415
Müller WEG, 340
Muñoz E, 389
Musey VC, 99
Mvere D, 183

Naemura M, 312
Narang PK, 274
Nassos PS, 176
Nauclér A, 422
Navikas V, 484
Nicolau C, 126
Noa E, 123
Norrgren H, 422
Northrup G, 99

Oakes JW, 332
O'Brien TR, 312
Oliva A, 450
Olivier C, 257
Olsson T, 484
Onorato IM, 395
Ordónez C, 1
Osborn JE, 26
O'Shaughnessy MV, 172
Ostroff SM, 176
Ott M, 20
Owen J, 401

Pandolfi F, 450
Paredes J, 138
Persson C, 484
Peruga A, 81
Petersen LR, 514
Phillips AN, 100
Phillips J, 305
Pierdominici M, 450
Plaeger S, 321
Polat H, 20
Poli G, 442
Pomerantz RJ, 332
Potler C, 315
Pousak T, 249
Putkonen P, 1

Quinti I, 450

Rainaldi L, 450
Ramirez KL, 193
Ratner L, 138
Ray P, 429
Reingold AL, 176
Rekart M, 172
Remick S, 315
Rezza G, 313
Rice J, 43
Rogers M, 280
Rojko JL, 11
Rolo FM, 123
Romeu J, 98
Rosenswajg M, 204
Rouse DJ, 401

Ruffault A, 243
Ruiz L, 98

Sabin CA, 100
Sahai J, 274
Saint-Antoine P, 257
Salamina G, 297
Salamon R, 415
Salzberg AM, 314
Saunders CA, 168
Saverino D, 227
Schacker T, 145
Schechter MT, 162
Schröder HC, 340
Schwoebel V, 74
Sell S, 211
Sellors JW, 523
Serraino D, 313
Sève A-P, 340
Shafer RW, 100
Shamu R, 183
Shao J, 408
Sharp V, 315
Shaw GM, 305
Shaw-Taylor Y, 193
Sheff B, 51
Sidhu J, 514
Simon CP, 101, 315
Simonon A, 415
Simpson DM, 153
Sinha SD, 99
Sirera G, 98
Sjöberg R, 103
Sodroski J, 429
Steimer K, 429
Stempien M, 264
Strigle SM, 206
Sugar AM, 168
Swai N, 408
Sweet RL, 359

Taelman H, 415
Tagliati M, 153
Taylor E, 89
Taylor H, 249
Temoshok LR, 36
Theis C, 340
Thielman NM, 408
Tong WP, 138
Torelli G, 311
Tosi P-F, 126
Troiani L, 51
Trovato R, 311
Tseng CK, 211
Turner BJ, 371
Tyor WR, 379

Uduman SA, 238
Unadkat JD, 145
Urdea M, 264
Ushijima H, 340

Vago L, 311
Valle MT, 227
Van de Perre P, 415
van der Horst CM, 51
Verdier M, 318
Vermund SH, 81, 401
Virochsiri K, 36
Vlahov D, 89, 291
Voigt R, 162
Voyer H, 257

Wadell G, 103
Wahren B, 484
Wainberg MA, 123
Wallmark E, 51
Walts AE, 206
Wang J-P, 145
Wang N-f, 103
Ward E, 81
Weinstein RA, 286
Weinstock HS, 514
Weiss KB, 193
Weissman D, 442
Wesselingh SL, 379
White A, 280
Whitehead E, 429
Wilkinson JG, 114
Winters MA, 100
Withum D, 395
Wong LC, 291

Yajko DM, 176
Yakrus MA, 176

Zadra JN, 162
Zhang Y-j, 103

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
9:528–532 © 1995 Lippincott-Raven Publishers, Philadelphia

Journal of Acquired Immune Deficiency Syndrome
Volume 9, 1995

Subject Index

Africa
  HIV, HTLV and *Treponema pallidum* infections in, 422
  natural history of HIV-1 infection in women of, 415
AIDS
  active HHV-6 infection of CNS in, 69
  cryptococcal pneumonia in, 168
  diabetes insipidus in, 99
  diagnosis and screening using clinical criteria for, 408
  human herpesvirus-6 in development of, 389
  incubation period of, 297
  Kaposi's sarcoma in women with, 313
  Pneumocystis carinii pneumonia as defining disease of, 74
  score cards for care of, 290
  surveillance of in Japan, 312
AIDS vaccine
  animal model and, 429
  progress toward, 26
Allele-specific primers, 264
Amplicor HIV-1 test, clinical evaluation of, 257
Animal model
  of SHIV infection, 429
  of ZDV treatment, 114
Antigen-presenting cells, HIV, 459
Anti-HIV-1 therapy, 126
Antiretrovirals, for nucleoside analogue-associated peripheral neuropathy, 153
Antisense RNA, 349
Antiviral therapy, 126
  HIV persistence and, 459
Apoptosis
  HIV persistence and, 459
  in mononuclear cell mortality, 450
Atovaquone, for *Pneumocystis carinii* pneumonia, 280
AZT. *See* Zidovudine

B cells, HIV-1 reverse transcriptase and, 58
Baboons, SHIV infections in, 429
Behavioral challenge, of HIV vaccine trials, 30
Bioelectrical impedance analysis, as survival predictor, 20
Blood donors, HIV risk factors in, 183

Cachexia, in weanling cats with feline leukemia virus, 11
Calorimetry, indirect, in weanling cats, 11
Carbohydrate-binding protein 35 expression, 332
Cats
  acute feline leukemia virus in, 11
  zidovudine therapy for viremia in, 114
CD4 cells
  with AZT treatment, 243
  below 250/mm^3, 98
  disease progression and, 51
  HIV infection progression and, 450
  HIV persistence and, 459
  HIV phenotype and decline of, 101
  loss with recent HIV infection, 291
  recombinant, 126
  recombinant soluble, 145
CD4+ T cells, HIV T epitopes and, 227
Cell-surface complement regulatory proteins, diminished expression of, 249
Central nervous system, active HHV-6 infection of, 69
Cervical intraepithelial neoplasia, in HIV-1 infected women, 361
Chemotherapy, for FIV viremia, 114
Children, cell-surface complement regulatory proteins in, 249
Chinese HIV-1 strain, morphogenesis of, 103
Chromatin, in HIV-1 gene expression, 332
Clinical case definitions, in Tanzania, 408
Clinical isolates, of membrane CD4, 126
Clinical outcome, with zidovudine treatment, 243
Codon 215 mutation, 264
  HVI phenotype and, 101
Cohort study, Kigali, 415
Coinfection, of HHV-6 and HIV, 389
Complement regulatory proteins, 249
Cryptococcal pneumonia, 168
Cryptococcosis, declining incidence of, 206
Cuba, V3 region sequences in, 123
Cytokines, in HIV production, 442
Cytomegalovirus infection, HHV-6 and, 389
Cytotoxic response, HIV persistence and, 459
Cytotoxic T cells, resistance to, 321

Decay-accelerating factor, 249
Decision analysis, in preventing vertical HIV transmission, 401
Dementia complex, HIV-associated, 379
Demyelination, with HHV-6 infection, 69

Developing countries, limiting HIV spread in, 500
Diabetes insipidus, in AIDS, 99
Diagnosis, clinical criteria in, 408
Didanosine
  for nucleoside analogue-associated peripheral neuropathy, 153
  phase I evaluation of, 274
Differential diagnosis, of cryptococcal pneumonia, 168
Disease progression
  apoptosis-related mononuclear cell mortality and, 450
  immunodominant epitope regions of HIV-1 RT and, 58
  predictors of in women, 43
  transient high HIV-1 titers and, 51
Drug interaction, with rifabutin and didanosine, 274
Drug users, HTLV-II seroconversion among, 89

Editorial, 359
Energy balance, with acute feline leukemia virus, 11
Environment, *Mycobacterium avium* complex in, 176
Erratum, Role of the primary infection in epidemics of HIV infection in gay cohorts, 102
Etoposide, with Kaposi's sarcoma, 138
Experimental trials, non-placebo controlled in prisons, 315

Feline immunodeficiency virus, zidovudine for, 114
Feline leukemia virus, altered energy balance and growth inhibition with, 11
Fetus, zidovudine effects on, 209
Fever, disease progression and, 51
Fibroblast-derived factors, HIV infection progression and, 450
Financing, of HIV hospital care, 193
FIV viremia, early suppression of by ZDV, 114
Foamy viruses, in Graves' disease, 99
Food, *Mycobacterium avium* complex in, 176

gp120 specific clones, 227
Graves' disease, absence of human spumaretrovirus sequences in, 99
Growth inhibition, with acute feline leukemia virus, 11
Guinea-Bissau, HIV-2-associated mortality in occupational cohort of, 422
Gynecologic disease, in HIV-1 infected women, 359, 361

Hepatitis C, second-generation enzyme immunoassay, 97
Heterosexual transmission
  in female sex workers, 395
  HTLV-I and, 81
HIV antibody, saliva test for, 172
HIV experimental trials, non-placebo controlled, 315
HIV-1 forming inclusion bodies, in Jurkat-*tat* III cells, 103
HIV-1 gene expression, sodium butyrate stimulated, 332
HIV-1 infection
  carbohydrate-binding protein 35 expression in, 332
  codon 215 mutant and wild-type, 264
  disease progression and titers of, 51
  four-year natural history of, 415
  gynecologic disease with, 359, 361
  HHV-6 and, 389
  membrane CD4 in transmission of, 126
  multiple superinfections and, 211
  prevalence, incidence, and risks for in female sex workers, 395
  proviral DNA of, 257
  symptomatic *vs.* asymptomatic primary, 305
  Treponema pallidum infection and, 422
HIV-2 infection, *Treponema pallidum* infection and, 422
HIV isolates, V3 region sequences in, 123
HIV phenotype, association with virus burden, codon 215 mutation and CD4 cell decline, 101
HIV replication, 204
  protection of T-cell line from, 349
HIV-1 reverse transcriptase, immunodominant epitope regions of, 58
HIV vaccine
  incentives and disincentives to research on, 36
  social and behavioral challenges of, 30
HIV-positive women
  Papanicolaou smear underutilization in, 206
  prenatal care of, 371
Homosexual men, nutritional intake in, 162
Hospital care, for HIV-infected persons, 193
Hospitalization rates, for HIV treatment, 193
Human herpesvirus-6 (HHV-6)
  in AIDS patients, 69
  frequency of genome in lymphoproliferative disorders, 311
  in HIV infection course, 389
Human herpesvirus infection, central nervous system, 69
Human immunodeficiency virus (HIV)
  apoptosis-related mortality of mononuclear cells and, 450
  in baboons, 429
  bioelectrical impedance analysis as survival predictor in, 20
  CD4 T cell loss with, 291
  cryptococcosis incidence in, 206
  cytokine synergy in enhancing cell production of, 442
  diagnosis and screening using clinical criteria for, 408
  gynecologic disease with, 359, 361
  HHV-6 in course of, 389
  high HIV-1 titers and progression of, 51
  high-dose, IV rsCD4 in, 145
  increased cytokine expression in, 484
  initial period of high infectivity and spread of, 314, 315
  Kaposi's sarcoma associated with, 138
  life span of membrane CD4 in RBCs in, 126
  limiting spread of in developing countries, 500
  mother-to-infant transmission of, 238
  nucleoside analogue-associated peripheral neuropathy in, 153
  nutritional intake and, 162

pathogenesis of neurological diseases with, 379
persistence of, 459
plasma viremia in prognosis of, 243
predictors of progression in women, 43
preventing vertical transmission of, 401
seroprevalence surveys of, 490
seroprevalence trends in STD clinics, 514
T epitopes of, 227
target cell resistance to cytotoxic lysis of, 321
transfusion-associated, 183
Treponema pallidum infection and, 422
Human T-cell lymphotropic virus (HTLV), *Treponema pallidum* infection and, 422
Human T-cell lymphotropic virus (HTLV) antibody enzyme immunoassays, lack of specificity of, 523
Human T-cell lymphotropic virus type I (HTLV-I)
indeterminate Western blot patterns of, 316, 318
risk factors for, 81
risk factors for among heterosexual STD clinic attenders, 81
Human T-cell lymphotropic virus type II (HTLV-II), incidence and risk factors among injecting drug users, 89

Immunoassay, hepatitis C second-generation enzyme, 97
Immunodeficiency, thymus immunopathology in, 1
Immunodominant epitope regions, HIV-1 reverse transcriptase, 58
Immunoglobulin G, HIV-1+, 58
Immunology, of symptomatic *vs.* asymptomatic primary HIV-1 infection, 305
Immunotherapy, HIV-1 reverse transcriptase and, 58
Incidence
in female sex workers, 395
of HIV, HTLV and *Treponema pallidum* infections, 422
for HTLV-II seroconversion among injecting drug users, 89
serial HIV seroprevalence in predicting, 490
Inclusion bodies, HIV-1 forming, 103
India, mother-to-infant HIV transmission in tribal women of, 238
Infectivity
CD4 T lymphocyte loss and, 291
nonlinear effect on HIV spread, 314, 315
Interleukin-6
in HIV production, 442
increased mRNA expression of, 484
target cell resistance and, 321
Interleukin-10
in HIV production, 442
increased mRNA expression of, 484
Interleukin-2, HIV infection progression and, 450
Italy, Kaposi's sarcoma in women with AIDS in, 313

Jamaica, STD clinic in, 81
Japan, surveillance of AIDS in, 312

Kaposi's sarcoma
etoposide for, 138
in Italian women with AIDS, 313

Lectin, expression of carbohydrate-binding protein 35 by, 332
Letters to Editor
Absence of evidence for human spumaretrovirus sequences in patients with Graves/ disease, 99
Association between HIV phenotype, virus burden, codon 215 mutation and CD4 cell decline, 101
Association between HIV phenotype, virus burden, codon 215 mutation and CD4 cell decline (author's reply), 101
Decline in the incidence of cryptococcosis among HIV-infected patients, 206
Diabetes insipidus and AIDS, 99
Frequency of HHV-6 genome detection in AIDS-related lymphoproliferative disorders, 311
High specificity of hepatitis C second-generation enzyme immunoassay in HIV-infection patients, 97
HIV replication and lack of alteration of phytohemagglutinin-induced lymphokine production by PBMCs, 204
HTLV-I "indeterminate" Western blot patterns observed in sera from tropical regions: the situation revisited, 316
HTLV-I "indeterminate" Western blot patterns observed in sera from tropical regions: the situation revisited (authors' reply), 318
Lack of short-term efficacy of *N*-acetyl-L-cysteine in HIV-positive patients with CD4 cell counts $<250/mm^3$, 98
Lack of specificity of HTLV antibody enzyme immunoassays, 523
Nonlinear effect of the initial period of high infectivity on the spread of HIV in the United States, 314
Nonlinear effect of the initial period of high infectivity on the spread of HIV in the United States (authors' reply), 315
Non-placebo controlled HIV experimental trials in prisoners, 315
Non-placebo controlled HIV experimental trials in prisoners (author's reply), 315
Risk for Kaposi's sarcoma among Italian women with AIDS, 313
Surveillance for the acquired immunodeficiency syndrome in Japan, 312
Underutilization of the Papanicolaou smear in HIV-positive women, 206
Zidovudine in pregnancy: is it dangerous for the fetus?, 209
Zidovudine use in pregnancy, 208
Zidovudine use in pregnancy (authors' reply), 208
Lymphoproliferative disorders, frequency of HHV-6 genome detection in, 311

Macrophages, in HIV-associated neurological disease, 379

Malnutrition, in HIV patients, 20
Mathematical model, of HIV transmission dynamics, 500
Medicaid, and prenatal care of HIV-infected women, 371
Membrane cofactor protein, 249
Meningitis, cryptococcal, 168
Messenger RNA, increased cytokine expression of, 484
Microglia, in HIV-associated neurological disease, 379
Molt-3 cells, in HIV-1 infection, 332
Monkeys, progressive SIVsm infection in, 1
Mother-to-infant transmission, in Indian tribal women, 238
Multidrug therapy, for *Mycobacterium avium* complex, 133
Mycobacterium avium complex
in HIV-infected individual's environment, 176
multidrug therapy for, 133

N-Acetyl-L-cysteine, short-term efficacy of, 98
Natural history, of HIV-1 infection in African women, 415
Neurological disease, HIV-associated, 379
Nuclear factor-kappa B, in HIV-1 stimulation, 332
Nuclear lectin, expression of carbohydrate-binding protein 35 by, 332
Nucleoside analogues, peripheral neuropathy and, 153
Nutrition, in homosexual men, 162

p24 Antigenemia, 243
p66 specific clones, 227
Papanicolaou smear, underutilization of, 206
Pelvic inflammatory disease, in HIV-1 infected women, 361
Perforin, increased mRNA expression of, 484
Perinatal transmission, incubation period and, 297
Peripheral blood mononuclear cells (PBMCs)
apoptosis-related mortality of, 450
HIV infection of, 249
HIV-1 proviral DNA in, 257
increased cytokine expression in, 484
phytohemagglutinin-induced lymphokine production by, 204
Peripheral neuropathy, nucleoside analogue-associated, 153
Pharmacokinetics, of high-dose, IV rsCD4, 145
Phase I study
of high-dose, IV rsCD4, 145
of rifabutin and didanosine, 274
Phytohemagglutinin-induced lymphokine, production pattern of, 204
Plasma viremia
disease progression and, 51
prognostic value of in AZT treatment, 243
Pneumocystis carinii pneumonia
as AIDS defining disease, 74
treatment IND protocol for, 280
Polymerase chain reaction
comparison of procedures of, 264
in detecting HIV-1 proviral DNA, 257
Predictors, of HIV disease progression in women, 43
Pregnancy
prenatal care with HIV infection, 371
zidovudine use during, 208, 209
Prenatal care, of HIV-infected women, 371
Prevalence, of HIV, HTLV and *Treponema pallidum* infections, 422
Prisoners, non-placebo controlled HIV experimental trials in, 315
Prognosis
bioelectrical impedance analysis in, 20
plasma viremia in, 243
Progression markers, of HIV/AIDS, 490
Prophylactic therapy, incubation period and, 297
Prostitutes, HIV-1 infection in, 395
Pulmonary cryptococcosis, 168

Rabbits, HIV-1 infection in, 211
Rash, disease progression and, 51
Red blood cells, life span of membrane CD4 in, 126
Research participation, incentives and disincentives to, 36
Retrovirus, in weanling cats, 11
Reverse transcriptase, HIV-1, 58
Rifabutin, phase I evaluation of, 274
Risk factors
in blood donors, 183
for HTLV-I, 81
for HTLV-II among injecting drug users, 89
RNA polymerase III, 349

Saliva test, accuracy of, 172
Screening
saliva test in, 172
using clinical criteria, 408
Sensory neuropathy, HIV-associated, 379
Sequencing, of envelope V3 region, 123
Seroconversion
of HTLV-II among drug users, 89
of primary HIV-1 infection, 305
Seroprevalence
serial HIV surveys, 490
surveys of in female sex workers, 395
trends in STD clinics, 514
Sexually transmitted disease
HTLV-I risk with, 81
trends in, 514
SHIV infection, in baboons, 429
Simian immunodeficiency virus
in baboons, 429
thymic immunopathology and, 1
SIVmac, 429
Sodium butyrate, HIV-1 gene expression and, 332
Soil, *Mycobacterium avium* complex in, 176
Spumaretroviruses, absence of in Graves' disease, 99
Stavudine, for nucleoside analogue-associated peripheral neuropathy, 153
Superinfections, HIV-1 activation and, 211
Surveillance
of AIDS in Japan, 312

of HIV seroprevalence, 490
of *Pneumocystis carinii* pneumonia as AIDS-defining disease, 74
saliva test in, 172
Survival
bioelectrical impedance analysis in predicting, 20
multidrug therapy effects on, 133
Syncytium-inducing phenotype, disease progression and, 51
Syphilitic infections, incidence and prevalence in Guinea-Bissau, 422

T cells
cytotoxic, 321
protection from HIV replication, 349
T epitopes, molecular and structural context of, 227
Tanzania, clinical criteria in, 408
Teaching hospital, in care of HIV-infected persons, 193
Thymus, immunopathology and progressive SIVsm infection, 1
Title 19, and prenatal care of HIV-infected women, 371
Transcriptional activation, in HIV production, 442
Transfusion-associated HIV, strategies to avert, 183
Transmission dynamics studies, 500
Treatment investigational new drug (IND) protocol, for *Pneumocystis carinii* pneumonia, 280
Trends
analysis in hospital care for HIV-infected persons, 193
in HIV seroprevalence, 514
Treponema pallidum infection, incidence and prevalence in Guinea-Bissau, 422
Tropical regions, HTLV-I indeterminate Western blot patterns of sera from, 316, 318
Tuberculosis, in African women, 415
Tumor necrosis factor-α, 379
Tumor necrosis factor, in HIV production, 442
Tumor necrosis factor-α, increased mRNA expression of, 484

United States, HIV spread in, 314, 315
Utilization, for HIV treatment, 193

V3 region, of Cuban HIV-1 isolates, 123
VA1 RNA, 349
Vaccine
AIDS, 26
HIV persistence and, 459
HIV-1 reverse transcriptase and, 58
incentives and disincentives to research on, 36
for SHIV infection, 429
social and behavioral challenges of, 30
Vacuolar myelopathy, HIV-associated, 379
Vacuolization, of HIV-1 forming inclusion bodies, 103
Vaginitis, in HIV-1 infected women, 361
Vertical transmission
incubation period of, 297
in tribal women of India, 238
zidovudine in preventing, 401
Viral load, determination of, 264
Viral-specific primers, 264
Viremia
early suppression of by ZDV, 114
high-dose, IV rsCD4 in, 145
prognostic value of in AZT treatment, 243
Virology, of symptomatic *vs.* asymptomatic primary HIV-1 infection, 305
Virus burden, HVI phenotype and, 101
vpu gene, 103

Water, *Mycobacterium avium* complex in, 176
Weight loss, in homosexual men, 162
Western blot, HTLV-I indeterminate patterns of, 316, 318
White matter disease, in AIDS patients, 69
Women
gynecologic disease in HIV-1 infected, 359, 361
Kaposi's sarcoma in, 313
natural history of HIV-1 infection in, 415
Papanicolaou smear underutilization in, 206
predictors of HIV progression in, 43
prenatal care of, 371
sex workers, HIV-1 infection in, 395

Zalcitabine, for nucleoside analogue-associated peripheral neuropathy, 153
Zidovudine
in early suppression of FIV viremia, 114
plasma viremia in prognosis with, 243
during pregnancy, 208, 209
in preventing vertical HIV transmission, 401
resistance to, 264
Zidovudine/didanosin combination therapy, resistance to, 264
Zimbabwe, blood donor deferral in, 183